מדינה: ארצות הברית
שפה: אנגלית
מקור: NLM (National Library of Medicine)
zolmitriptan (UNII: 2FS66TH3YW) (zolmitriptan - UNII:2FS66TH3YW)
Curae Pharma360 Inc
ORAL
PRESCRIPTION DRUG
Zolmitriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use - Only use zolmitriptan tablets if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan tablets treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan tablets are administered to treat any subsequent attacks. - Zolmitriptan tablets are not indicated for the prevention of migraine attacks. - Safety and effectiveness of zolmitriptan tablets have not been established for cluster headache. Zolmitriptan tablets are contraindicated in patients with: - Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or c oronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions (5.1) ] - Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conductio
2.5 mg Tablets – Yellow colored, round, biconvex film-coated tablets debossed with 101 on one side and deep breakline on other side and are supplied in cartons containing a blister pack of 6 tablets (NDC 73358-101-06) 5 mg Tablets – Pink colored, round, biconvex film-coated tablets debossed with 102 on one side and plain on other side and are supplied in cartons containing a blister pack of 3 tablets (NDC 63548-0102-3). Store Zolmitriptan tablets at 20° to 25°C (68° to 77°F); [see USP]. Protect from light and moisture.
Abbreviated New Drug Application
ZOLMITRIPTAN- ZOLMITRIPTAN TABLET, FILM COATED CURAE PHARMA360 INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ZOLMITRIPTAN SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZOLMITRIPTAN. ZOLMITRIPTAN TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1997 RECENT MAJOR CHANGES Dosage and Administration (2.1, 2.3, 2.4) 09/2012 Warnings and Precautions (5.6) 09/2012 INDICATIONS AND USAGE Zolmitriptan is a serotonin (5-HT) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) DOSAGE AND ADMINISTRATION Recommended starting dose: 1.25 mg or 2.5 mg (2.1) Maximum single dose: 5 mg (2.1) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period (2.1) Moderate or Severe Hepatic Impairment: 1.25 mg recommended (2.3, 8.6) DOSAGE FORMS AND STRENGTHS Tablets: 2.5 mg functionally-scored (3) Tablets: 5 mg (not scored) (3) CONTRAINDICATIONS History of coronary artery disease (CAD) or coronary vasospasm (4) Symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4) History of stroke, transient ischemic attack, or hemiplegic or basilar migraine (4) Peripheral vascular disease (4) Ischemic bowel disease (4) Uncontrolled hypertension (4) Recent (within 24 hours) use of another 5-HT agonist (e.g., another triptan), or an ergotamine- containing medication (4) Monamine oxidase (MAO)-A inhibitor used in past 2 weeks (4) Known hypersensitivity to zolmitriptan tablets (4) WARNINGS AND PRECAUTIONS _Myocardial Ischemia/Infarction, and Prinzmetal Angina_: Perform cardiac evaluation in patients with multiple cardiovascular risk factors (5.1) _Arrhythmias_: Discontinue zolmitriptan if occurs (5.2) _Chest/Throat/Neck/Jaw Pain, Tightness, and Pressu קרא את המסמך השלם